NCT04210349View on ClinicalTrials.gov

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

7,106

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent Influenza Vaccine

Pharmaceutical form: Suspension for injection Route of administration: intramuscular

BIOLOGICAL

Trivalent Influenza Vaccine 1 SP Shz TIV1

Pharmaceutical form: Suspension for injection Route of administration: intramuscular

BIOLOGICAL

Trivalent Influenza Vaccine 2 SP Shz TIV2

Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Trial Locations (7)

450002

Investigational Site Number 1562000, Zhengzhou

453200

Investigational Site Number 1562002, Xinxiang

476000

Investigational Site Number 1562001, Shangqiu

650022

Investigational Site Number 1561000, Kunming

677001

Investigational Site Number 1561001, Lincang

Investigational Site Number 1561002, Lincang

Investigational Site Number 1561003, Lincang

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04210349 - Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age | Biotech Hunter | Biotech Hunter